Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.
AKT
E-cadherin
chemoprevention
diffuse gastric cancer
synthetic lethality
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Sep 2019
13 Sep 2019
Historique:
received:
29
07
2019
revised:
04
09
2019
accepted:
10
09
2019
entrez:
22
9
2019
pubmed:
22
9
2019
medline:
22
9
2019
Statut:
epublish
Résumé
The
Identifiants
pubmed: 31540244
pii: cancers11091359
doi: 10.3390/cancers11091359
pmc: PMC6769709
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Health Research Council of New Zealand
ID : 17/16
Références
PLoS One. 2017 Sep 18;12(9):e0183891
pubmed: 28922362
Cell. 2015 Feb 26;160(5):977-989
pubmed: 25723171
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91
pubmed: 21464312
Curr Biol. 1999 Feb 11;9(3):R93-6
pubmed: 10021376
J Med Genet. 2015 Jun;52(6):361-74
pubmed: 25979631
Crit Rev Oncol Hematol. 2018 Jan;121:11-22
pubmed: 29279096
Mol Cancer Ther. 2012 Jan;11(1):154-64
pubmed: 22057914
J Biol Chem. 1999 Jul 2;274(27):19347-51
pubmed: 10383446
Mol Endocrinol. 2005 Oct;19(10):2564-78
pubmed: 15928314
J Natl Cancer Inst. 2015 Feb 16;107(3):null
pubmed: 25688104
Science. 1998 Jan 30;279(5351):710-4
pubmed: 9445477
Nat Commun. 2018 Mar 8;9(1):1012
pubmed: 29520031
Fam Cancer. 2019 Jul;18(3):363-367
pubmed: 30989426
Med Oncol. 2015 Jul;32(7):206
pubmed: 26087957
Mol Cancer Ther. 2015 May;14(5):1213-23
pubmed: 25777964
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12895-900
pubmed: 20615979
Mol Cell. 2014 Jun 19;54(6):987-98
pubmed: 24882208
Am J Hum Genet. 2019 Mar 7;104(3):484-491
pubmed: 30803705
Cell. 1997 Oct 17;91(2):231-41
pubmed: 9346240
Cancer. 2015 Jul 1;121(13):2193-7
pubmed: 25827820
Gastric Cancer. 2019 Mar;22(2):273-286
pubmed: 30066183
Mol Cell Biol. 1999 Aug;19(8):5800-10
pubmed: 10409766
Breast Cancer Res. 2013 Nov 19;15(6):R110
pubmed: 24252402
Sci Rep. 2015 Dec 11;5:17162
pubmed: 26657992
J Med Chem. 2012 Sep 27;55(18):8110-27
pubmed: 22934575
Pharmacol Ther. 2017 Apr;172:101-115
pubmed: 27919797
J Clin Invest. 2005 Aug;115(8):2128-38
pubmed: 16007268
Oncol Lett. 2013 Mar;5(3):1043-1047
pubmed: 23426647
Virchows Arch. 2008 Nov;453(5):449-55
pubmed: 18841391
BMC Cancer. 2014 Jul 30;14:552
pubmed: 25079037
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Cell Mol Life Sci. 2008 Nov;65(23):3756-88
pubmed: 18726070
JAMA Oncol. 2015 Apr;1(1):23-32
pubmed: 26182300
Mol Cancer Ther. 2010 Mar;9(3):706-17
pubmed: 20197390
Curr Med Chem. 2011;18(18):2727-42
pubmed: 21649580
Hum Mutat. 1999;14(3):249-55
pubmed: 10477433
Br J Cancer. 2009 Apr 21;100(8):1213-8
pubmed: 19319136
PLoS One. 2010 Sep 23;5(9):e12913
pubmed: 20886116
Methods Mol Biol. 2002;180:175-204
pubmed: 11873650
Methods. 2013 Jun 1;61(2):156-64
pubmed: 23607990
Nat Chem Biol. 2009 Jul;5(7):484-93
pubmed: 19465931
PLoS One. 2018 Feb 6;13(2):e0192464
pubmed: 29408858
Stem Cells Int. 2016;2016:3710836
pubmed: 26697073
J Biomol Screen. 2015 Dec;20(10):1286-93
pubmed: 26384394
Int J Oncol. 2016 Mar;48(3):869-85
pubmed: 26698230